Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

• Váldodahkkit: Alexandra B. Kimball (Dahkki), Thomas Luger (Dahkki), Alice Gottlieb (Dahkki), Luis Puig (Dahkki), Roland Kaufmann (Dahkki), Russel Burge (Dahkki), Chen-Yen Lin (Dahkki), Gil Yosipovitch (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Medical Journals Sweden, 2017-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance thera...